Evoke Pharma, Inc.

NasdaqCM EVOK

Evoke Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 9.07

Evoke Pharma, Inc. Revenue Per Share is USD 9.07 for the Trailing 12 Months (TTM) ending September 30, 2024, a -41.23% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Evoke Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 15.44, a 85.47% change year over year.
Evoke Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 8.32, a 38.48% change year over year.
Evoke Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 6.01, a 0.00% change year over year.
Evoke Pharma, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: EVOK

Evoke Pharma, Inc.

CEO	Mr. Matthew J. D'Onofrio MBA
IPO Date	Sept. 25, 2013
Location	United States
Headquarters	420 Stevens Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Key trends

Past 5 years